系统性红斑狼疮缓解定义:两项随机临床试验的事后分析
本研究在BLISS-52(n=865)和BLISS-76(n=819)试验中事后应用DORIS缓解定义,评估其作为SLE研究结局指标的适用性。结果显示DORIS缓解定义总体达标率低,临床SLEDAI-2K=0定义达标率高于BILAG D/E定义,允许血清学活动和维持治疗的定义达标率更高。将持续达标加入on therapy定义后可区分贝利尤单抗10 mg/kg与安慰剂组。
要点
- 临床SLEDAI-2K=0定义达标率高于BILAG D/E定义,允许血清学活动和维持治疗者达标率更高。
- 将持续达标加入on therapy定义后可区分贝利尤单抗10 mg/kg与安慰剂组。
核心结论
- DORIS缓解定义总体达标率低,临床SLEDAI-2K=0定义优于BILAG D/E定义,允许血清学活动和维持治疗的定义达标率更高,持续达标可区分贝利尤单抗与安慰剂。
研究设计与样本
- 事后分析,应用DORIS缓解定义于BLISS-52(n=865)和BLISS-76(n=819)临床试验的多个时间点。
- 定义在允许治疗(on therapy,泼尼松≤5 mg/day及维持免疫抑制剂和生物制剂)和不允许治疗(off therapy)情况下评估,抗疟药在所有定义中允许。
- 定义不论血清学活动(抗dsDNA阳性或低C3/C4)和血清学正常均应用,并应用允许泼尼松≤10 mg/day的修改版DORIS on therapy定义。
主要发现
- 安慰剂组与贝利尤单抗组之间未检测到显著差异。
- 某些on therapy定义的持续达标显示能区分接受贝利尤单抗10 mg/kg和安慰剂的患者。
关键数值与推荐
- DORIS 1定义要求临床SLEDAI-2K=0(排除血清学项),DORIS 2定义要求所有BILAG域评分为D或E。
- on therapy允许低剂量糖皮质激素(泼尼松≤5 mg/day)和维持免疫抑制剂及生物制剂,抗疟药在所有定义中允许。
临床怎么用
- 临床SLEDAI-2K=0定义在SLE试验中达标率高于BILAG D/E定义,可优先考虑用于缓解评估。
- 允许血清学活动和维持治疗的定义达标率更高,更适用于临床试验结局评价。
- 将持续达标纳入on therapy定义可提高区分贝利尤单抗与安慰剂的能力。
局限性
- 本研究为事后分析,结果需在前瞻性研究中验证。
- 安慰剂与贝利尤单抗组间未检测到显著差异,部分定义区分能力有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Definitions Of Remission In Systemic Lupus Erythematosus (DORIS) international task force has proposed remission definitions that are amenable to scientific testing. In this study, we aimed to evaluate their suitability as outcome measures in studies of systemic lupus erythematosus. METHODS: In this post-hoc study, we applied remission definitions as specified by DORIS criteria at multiple timepoints in the BLISS-52 (n=865) and BLISS-76 (n=819) clinical trials. All definitions required physician's global assessment scores less than 0·5 (possible range 0-3). The DORIS 1 definitions required clinical systemic lupus erythematosus disease activity index 2000 (SLEDAI-2K)=0 (with serological items excluded). The DORIS 2 definitions required a score of D or E in all British Isles Lupus Assessment Group (BILAG) domains. The definitions were assessed in the trial populations both with (on therapy) and without (off therapy) treatment allowance-ie, low-dose glucocorticoids (prednisone ≤5 mg/day) and maintenance immunosuppressive and biological agents. Antimalarial agents were allowed in all definitions. The definitions were applied irrespective of serological activity (anti-double stranded DNA positivity, or low C3 or C4) and with normal serology. Finally, we applied modifications similar to DORIS on therapy but allowing higher prednisone doses (≤10 mg/day). FINDINGS: In the pooled dataset, the remission definition most frequently attained was the modified (prednisone ≤10 mg/day) DORIS 1a on therapy definition, which required a SLEDAI-2K score of 0 and permitted serological activity (237 [17·8%] of 1333 participants at week 52), followed by the unmodified (predisone ≤5 mg/day) DORIS 1 on therapy definition (140 [10·5%] of 1336 participants at week 52) based on these two definitions. We detected no significant difference between the placebo and belimumab groups. Proportions of patients achieving off therapy and BILAG-based definitions were low (≤0·9% at all timepoints). Sustained attainment of certain on therapy definitions showed an ability to discriminate between patients who received belimumab 10 mg/kg and patients who received placebo. INTERPRETATION: Attainment of DORIS remission definitions was infrequent overall. Use of clinical SLEDAI-2K=0 in the definitions yielded higher proportions of attainment than did use of BILAG D or E. Attainment was also higher using definitions that allowed for serological activity and maintenance treatment. Addition of the durability aspect to on therapy definitions led to an ability to discriminate between belimumab and placebo. FUNDING: Swedish Rheumatism Association, Professor Nanna Svartz Foundation, Ulla and Roland Gustafsson Foundation, Region Stockholm, and Karolinska Institutet Foundations.
引用
- Parodis I, Emamikia S, Gomez A, et al. Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials. Lancet Rheumatol. 2019. PMID: 38229393. doi:10.1016/S2665-9913(19)30049-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。